(Q37282274)

19 August 2017

1 reference

title

Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck (English)

1 reference

metastatic squamous cell carcinoma

19 August 2017

1 reference

1 reference

Jacques Bernier

1

1 reference

PubMed ID

18825142

19 August 2017

language of work or name

1 reference

30 September 2008

1 reference

Nature Clinical Practice Oncology

19 August 2017

1 reference

19 August 2017

5

1 reference

19 August 2017

12

1 reference

19 August 2017

705-713

1 reference

Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.

19 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Differential expression of epidermal growth factor receptor in human head and neck cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

The EGFR as a target for anticancer therapy--focus on cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemotherapeutic agents on squamous cell carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1228

7 January 2021

Identifiers

DOI

10.1038/NCPONC1228

1 reference

19 August 2017

1 reference

PubMed ID

18825142